SCHEMBL3012801

SCHEMBL3012801

CC(=O)N(c1ccccc1)c1cc(CN(CC(C)(C)C)C(=O)O)nn1-c1ccccc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.34
GRN P28799 1/20 0.34
SORT1 Q99523 1/20 0.34
NPSR1 Q6W5P4 2/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
SLC16A3 O15427 3/20 0.33
SLC16A1 P53985 3/20 0.33
RIPK1 Q13546 1/20 0.33
GRM5 P41594 1/20 0.32
JAK2 O60674 1/20 0.32
MAPK1 P28482 1/20 0.32
MEN1 O00255 1/20 0.32
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.32
POLB P06746 1/20 0.32
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32
MCTS1 Q9ULC4 1/20 0.32
LMNA P02545 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2838918 0.83 NPSR1 (0.37) ALDH1A1NPSR1CNR1CNR2SLC16A3
SCHEMBL3012799 0.79 HTR2C (0.49) ALDH1A1GRNSORT1NPSR1CNR1
SCHEMBL2836798 0.78 MEN1 (0.39) ALDH1A1NPSR1RIPK1MAPK1MEN1
SCHEMBL2838922 0.76 ALDH1A1 (0.43) ALDH1A1NPSR1RIPK1MAPK1MEN1
SCHEMBL3012796 0.75 RIPK1 (0.38) ALDH1A1RIPK1MAPK1
SCHEMBL18093107 0.73 CA1 (0.41) ALDH1A1GRNSORT1NPSR1POLB
SCHEMBL2838656 0.70 ALDH1A1 (0.39) ALDH1A1GRNSORT1NPSR1CNR1
SCHEMBL19182367 0.66 ALDH1A1 (0.39) ALDH1A1GRNSORT1NPSR1CNR1
SCHEMBL3432334 0.65 MAPK14 (0.48) GRNSORT1JAK2
SCHEMBL19181130 0.65 BCL2 (0.43) ALDH1A1NPSR1TSHRKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8334301-B2 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-18 US disclosed
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND NPY4R, NPY5R, NPY1R ALDH1A1 2505/4885GRN 3056/4885SORT1 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.